trial
as of 2026-07-01Pilot Study 1: Efficacy and Safety of Sublingual Dexmedetomidine (BXCL501) for the Treatment of Agitation in the Emergency Department
NCTId NCT05974527
at a glance
Phase 4 · Withdrawn
Enrollment 0 (actual)
Sponsored by Brigham and Women's Hospital
Primary completion 2025-09-30
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 4
Status
Withdrawn
Enrollment
0 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2023-09-01
Primary completion
2025-09-30
Eligibility
ALL · 18 Years
Interventions & indications
Sponsors
Brigham and Women's HospitalLead Sponsor
Sites
0 total
Facts & assertions
4 sourced
Enrollment
0
Phase
PHASE4
Primary Completion Date
2025-09-30
Status
WITHDRAWN
relationships
The graph out of here
lead_sponsor
company
indication